Skip to main content
SpringerLink
Log in

Harnblasenkarzinom

  • Chapter
Book cover Uroonkologie

Zusammenfassung

Die Suche nach Risikofaktoren dient der Identifizierung tumorverursachender Substanzen (Karzinogene). Erst die Identifizierung der Karzinogene ermöglicht einen präventiven Ansatz und eine günstige Beeinflussung berufsbedingt gefährdeter Personengruppen. Der ersten Mitteilung über Risikofaktoren, an einem Harnblasenkarzinom zu erkranken, über die Rehn berichtete, folgten zahlreiche experimentelle Publikationen zur chemischen Karzinogenese bei Ratten und Mäusen (Babaya et al. 1987; Irving et al. 1984; Ito 1984, 1988; Linn u. Rübben 1995; Shibata Ma et al. 1989). Leider haben diese Erkenntnisse bislang nur unzureichend Eingang in die Tumorprävention am Arbeitsplatz gefunden. Dies wird deutlich durch die nur geringe Anzahl von der durch die Berufsgenossenschaft anerkannten Harnblasenkarzinomerkrankungen (Norpoth u. Woitowitz 1994). So werden trotz der experimentell nachgewiesenen chemischen Karzinogenese von Harnblasentumoren bislang als größte Risikofaktoren das Alter und Geschlecht gesehen (Tabelle 4.1). Ursache ist die sehr lange Entwicklungszeit von der Karzinogenexposition bis zur Entwicklung eines manifesten Karzinoms, die im Mittel 24 Jahre beträgt und die Karzinogenidentifizierung erschwert. Dies macht deutlich, wie entscheidend die lange zurückreichende Berufsanamnese bei Patienten mit Harnblasenkarzinom zu werten ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abel PD, Thorpe SJ, Williams G (1989) Blood group antigen expression in frozen sections of presenting bladder cancer: 3-year prospective follow-up of prognostic value. Br J Urol 63:171–175

    Article  CAS  PubMed  Google Scholar 

  • Ackermann D, Biedermann C, Bailly G., Studer UE (1988) Treatment of superficial bladder tumors with intravesical recombinant interferon alpha 2a. Urol Int 43:85

    Article  CAS  PubMed  Google Scholar 

  • Aghaji AE, Mbonu OO (1989) Bladder tumours in Enugu, Nigeria. Br J Urol 64:399

    Article  CAS  PubMed  Google Scholar 

  • Ahlering TE, Lieskovsky G, Skinner DG (1984) Indication for urethrectomy in men undergoing single stage radical cystectomy for bladder cancer. J Urol 131:657

    CAS  PubMed  Google Scholar 

  • Althausen AF, Prout GR, Daly JJ (1976) Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116:575

    CAS  PubMed  Google Scholar 

  • Anderström C, Johansson SL, van Schulz L (1983) Primary adenocarcinoma of urinary bladder. Cancer 52: 1273

    Article  PubMed  Google Scholar 

  • Arger PH (1985) Diagnostic in bladder carcinoma. Urol Clin North Am 12:677

    CAS  PubMed  Google Scholar 

  • Badalament RA, Gay H, Cibas ES, Herr HW, Whitmore WF Jr, Fair WR, Melamed MR (1987) Monitoring intravesical bacillus calmette-guerin treatment of superficial bladder carcinoma by postoperative urinary cytology. J Urol 138:763

    CAS  PubMed  Google Scholar 

  • Babaya K, Takahashi S, Momose H et al. (1987) Effects of single chemotherapeutic agents in development of urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats Urol Res 15:329–334

    Article  CAS  PubMed  Google Scholar 

  • Baker WC, Devere White R, Rossitto PV, Hee Min B, Cardiff RD (1988) Quantitative analysis of keratin 18 in the urine of patients with bladder cancer. J Urol 140:436

    CAS  PubMed  Google Scholar 

  • Bardot F, Montie JE (1991) Urethral recurrence after cystoprostatectomy. J Urol 145:501

    Google Scholar 

  • Batata MA, Chu FCH, Hilaris BS (1981) Factors of prognostic and therapeutic significance in patients with bladder cancer. Int J Radiat Oncol Biol Phys 7:575

    Article  CAS  PubMed  Google Scholar 

  • Beck AD, Gaudin HJ, Bonham DG (1970) Carcinoma of the urachus. Br J Urol 42:555–562

    Article  CAS  PubMed  Google Scholar 

  • Beer M, Schmidt H, Riedl R (1989) Klinische Wertigkeit des präoperativen Stagings von Blasen- und Prostatakarzinomen mit NMR und Computertomographie. Urologe [A] 28:65

    CAS  Google Scholar 

  • Behrens J, Birchmeier W, Goodman SL, Imhof BA (1985) Dissociation of Madin-Darby canine kidney epithelial cells by the monoclonal antibody anti-Arc 1: Mechanistic aspects and identification of the antigen as a component related to uvomorulin. J Cell Biol 101:1307–1315

    Article  CAS  PubMed  Google Scholar 

  • Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: Epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108: 2435–2447

    Article  CAS  PubMed  Google Scholar 

  • Beisland HO, Seland P (1986) A prospective randomized study on neodymium-YAG laser irradiation versus TUR in the treatment of urinary bladder cancer. Scand J Urol Neprol 20:209

    Article  CAS  Google Scholar 

  • Benson RC (1991) Die Anwendung der photodynamischen Therapie zur Behandlung des therapieresisten-ten Carcinoma in situ. Urologe A 30:158

    PubMed  Google Scholar 

  • Birchmeier W, Weidner KM, Schipper J, Behrens J (1993) Molekulare Aspekte der Invasion von Krebszellen. In: Rübben H, Goepel M, Schmitz-Dräger BJ (Hrsg) Immuntherapie in der Uroonkologie. Springer, 1993 (1. Auflage)

    Google Scholar 

  • Blackard CE, Byar DP (1972) Veterans Administration Cooperative Urological Group: Results of a clinical trial of surgery and radiation in stages II and III carcinoma of the bladder. J Urol 198:875

    Google Scholar 

  • Blandy JP, England HR, Evans SJW (1980) T3 bladder cancer — the case for salvage cystectomy. Br J Urol 52:506

    Article  CAS  PubMed  Google Scholar 

  • Bloom HJG, Hendry WF, Wallace DM (1982) Treatment of T3 bladder cancer: controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy. Second report and review. Br J Urol 54:136

    Article  CAS  PubMed  Google Scholar 

  • Blumenreich MS, Needles B, Yagoda A, Sogani P, Grabstald H, Whitmore WF Jr (1982) Intravesical cis-platin for superficial bladder tumors. Cancer 50:863

    Article  CAS  PubMed  Google Scholar 

  • Böhm M, Totzeck B, Birchmeier W, Wieland I (1994) Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clin Exp Metastasis 12 (1): 55–62

    Article  PubMed  Google Scholar 

  • Boller K, Vestweber D, Kemler R (1985) Cell-adhesion molecule ovumorulin is localized in the intermediate junctions of adult intestinal epithelial cells. J Cell Biol 100:327–332

    Article  CAS  PubMed  Google Scholar 

  • Bouffioux C, Kurth KH, Bono A, Dosterlinck W, Kruger CB, De Pauw M, Sylvester R (0000) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. Engl J Urol 153:934–941

    Article  CAS  PubMed  Google Scholar 

  • Boyland E, Wallace DM, Avis PRD, Kinder CH (1964) Attempted prophylaxis of bladder cancer with 1,4-glucosaccharolactone. Br J Urol 36:563

    Article  CAS  PubMed  Google Scholar 

  • Bracken RB, McDonald MW, Johnson DE (1981) Cystectomy for superficial bladder cancer. Urology 18/5:459

    Article  CAS  PubMed  Google Scholar 

  • Brannan W, Ochsner MG, Fuselier HA Jr (1978) Partial cysteaomy in the treatment for transitional cell carcinoma of the bladder. J Urol 119:213

    CAS  PubMed  Google Scholar 

  • Brannan W, Fuselier HA, Ochsner M, Randrup ER (1981) Critical evaluation of 1-stage cystectomy — reducing morbidity and mortality. J Urol 125:640

    CAS  PubMed  Google Scholar 

  • Bredael JJ, Croker BP, Glenn DF (1980) The curability of invasive bladder cancer treated by radical cystectomy. Eur Urol 6:206

    CAS  PubMed  Google Scholar 

  • Brendler CB, Schlegel PN, Walsh PC (1990 a) Urethrectomy with preservation of potency. J Urol 144:270

    CAS  PubMed  Google Scholar 

  • Brendler CB, Steinberg GD, Marshall FF, Mostwin JL, Walsh PC (1990 b) Local recurrence and survival following nerve-sparing radical cystoprostatectomy. J Urol 144:1137

    Article  CAS  PubMed  Google Scholar 

  • Bringuier PP, Umbas R, Schaafsma HE, Karthaus HFM, Debruyne FMJ, Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53:3241–3245

    CAS  PubMed  Google Scholar 

  • Brosman SA (1982) Experienc with bacillus calmette-guérin in patients with superficial bladder cancer. J Urol 128:27

    CAS  PubMed  Google Scholar 

  • Brosman SA (1985) The use of bacillus calmette-guérin in the therapy of bladder carcinoma in situ. J Urol 134:36

    CAS  PubMed  Google Scholar 

  • Bush C, Price P, Norton J et al. (1991) Proliferation in human bladder carinoma measured by Ki67 antibody labelling: its potential clinical importance. Br J Cancer 64 (2): 357–360

    Article  CAS  PubMed  Google Scholar 

  • Byar D, Blackard C (1977) Comparisons of placebo, pyridoxine, and tropical thiotepa in preventing recurrence of stage I bladder cancer. Urology 6:556

    Article  Google Scholar 

  • Cairns P, Suarez V, Newman J, Crocker J (1989) Nucleolar organizer regions in transitional cell tumors of the bladder. Arch Pathol Lab Med 113 (11): 1250–1252

    CAS  PubMed  Google Scholar 

  • Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiology approach to bladder cancer. Lancet II: 842

    Article  CAS  PubMed  Google Scholar 

  • Case RAM, Pearson JT (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Part II: Further consideration of the role of aniline and of the manufacture of auramine and magenta (fuchsine) as possible causative agents. Br J Ind Med 11:213

    CAS  PubMed  Google Scholar 

  • Case RAM, Hosker ME, McDonald DB, Pearson JT (1954) Tumours of the urinary bladder in workman engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Br J Ind Med 11:75

    CAS  PubMed  Google Scholar 

  • Cole P (1971) Coffee-drinking and cancer of the lower urinary tract. Lancet 1:1335

    Article  CAS  PubMed  Google Scholar 

  • Cole P (1973) A population based study of bladder cancer. In: Doll R, Vodopija I (eds) Host environmental interactions in the aetiology of cancer in main. IARC Sci 7:83

    Google Scholar 

  • Coon JS, Weinstein RS, Summers JL (1982) Blood group precursor T-antigen expression in human urinary bladder carcinoma. AJCP 77/6:692

    CAS  PubMed  Google Scholar 

  • Cordonnier JJ (1974) Simple cystectomy in the management of bladder carcinoma. Arch Surg 108:19

    Article  Google Scholar 

  • Cox CE, Cass AS, Boyce WH (1968) Bladder cancer a 26-year review. Trans Am Assoc Genitourin Surg 60:22

    CAS  PubMed  Google Scholar 

  • Cramer JW, Miller JA, Miller EC (1960) N-hydroxylation: a new metabolic reaction observed in the rath with the carcinogen 2-acetylaminofluorine. J Biochem Chem 235:885

    CAS  Google Scholar 

  • Cummings KB, Mason JT Correa RJ Jr (1978) Segmental resection in the management of bladder carcinoma. J Urol 119:56

    CAS  PubMed  Google Scholar 

  • Cutler SJ, Young JL (1975) Third national cancer survey: incidence data. Natl Cancer Inst Monogr 41:1

    Google Scholar 

  • Debruyne FMJ, van der Meijden APM, Geboers ADH et al. (1988) BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer: first results of a randomized prospective trial. In: Dei Silverio F, Steg A (eds) International workshops in urology, new trends in bladder cancer chemotherapy, new trends in BPH etiopathogenesis. Acta Medica. Cannes 1987, p 235

    Google Scholar 

  • Deutz FJ, Rübben H, Küpper W, Hofstädter F (1988) Morphologie der Harnblase und des Darms nach Harnleiter-Sigmaimplantation unter Karzinogenexposition. 9. Symposium Experimentelle Urologie. Aachen, 16.–18.6.

    Google Scholar 

  • Dreicer R, Messing EM, Loehrer PJ, Trump DL (1990) Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an eastern cooperative oncology group pilot study. J Urol 144:1123

    CAS  PubMed  Google Scholar 

  • Dretler SP, Ragsdale BD, Leadbetter WF (1973) The value of pelvic lymphadenectomy in the surgical treatment of bladder cancer. J Urol 109:414

    CAS  PubMed  Google Scholar 

  • Duckrey H, Landschütz C, Ivankovic S (1969) Selektive Erzeugung von Blasenkrebs an Ratten. Zur Krebsforschung 73:371

    Article  Google Scholar 

  • Dunst J, Sauer R, Schrott KM, Kühn R, Wittekind C, Altendorf-Hofmann A (1994) Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 30:261–266

    Article  CAS  PubMed  Google Scholar 

  • Edsmyr F, Berlin T, Boman J et al. (1984) Intravesical therapy with adriamycin in patients with superficial bladder tumors. Eur Urol 6:132

    Google Scholar 

  • England HR, Molland EA, Oliver RTD, Blandy JP (1981) Principles of combination therapy. In: Oliver RTD, Henry WF, Bloom HJG (eds) Bladder cancer. Butterworths, London, pp 97–105

    Google Scholar 

  • Esrig D, Shi SR, Bochner BH et al. (1995) Prognostic importance of p53 and RB alterations in transitional cell carcinoma of the bladder. J Urol 153 (4): 536

    Google Scholar 

  • Fairchild WV, Spence CR, Solomon HD, Gangai MP (1979) The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122:163

    CAS  PubMed  Google Scholar 

  • Ferrari G, Righi E, Castagnetti G et al. (1995) p53 and BCL-2 Expression in the superficial bladder cancer. J Urol 153 (4): 533

    Google Scholar 

  • Ferraris G, Repetto E, Pisano PF, Albano D (1986) Recurrence during the chemoprophylactic treatment of superficial tumors of the bladder. J Urol 136:576

    CAS  PubMed  Google Scholar 

  • Fischer C, Terpe H, Weidner W, Storkel S, Gunthert U (1995) Significance of cell adhesion moleculares for dedifferentiated processes in renal cell carcinomas. J Urol 153 (4): 340

    Google Scholar 

  • Fitzpatrick JM, Khan O, Oliver RTD, Riddle PR (1979) Long-term follow-up in patients with superficial bladder tumor treated with intravesical epodyl. Br J Urol 51:545

    Article  CAS  PubMed  Google Scholar 

  • Flamm J, Bucher A, Höltl W, Albrecht W (1990) Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial. J Urol 144:260

    CAS  PubMed  Google Scholar 

  • Flamm J, Donner G, Oberleitner S, Hausmann R, Havelec L (1995) Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study. Eur J Cancer 31A (2): 143–146

    Article  CAS  PubMed  Google Scholar 

  • Flocks RH (1951) Treatment of patients with carcinoma of the bladder. JAMA 145:295

    Article  CAS  Google Scholar 

  • O’Flynn JD, Smith JD, Hanson JS (1975) Transurethral resection for the assessment and treatment of vesical neoplasms. A review of 800 consecutive cases. Eur Urol 1:38

    PubMed  Google Scholar 

  • Fradet Y (1989) Molecular markers of superficial and aggressive human bladder cancers. Proc Annu Meet Am Assoc Cancer Res 30:662–663

    Google Scholar 

  • Fradet Y, Tetu B, Veilleux C, Allard P (1994) Prevalence and clinical significance of p53, Rb and HER-2/neu expression in newly diagnosed superficial bladder tumors. Urol 151 (5): 859, 442A

    Google Scholar 

  • Freiha FS (1980) Complications of cystectomy. J Urol 123:168

    CAS  PubMed  Google Scholar 

  • Frixen U, Behrens J, Sachs M et al. (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 111:173–185

    Article  Google Scholar 

  • Gasser TC, Sauter G, Mihatsch MJ, Moch H, Waldman FM (1995) Chromosome 17 heterogeneity in bladder cancer: association with p53 gene alterations and tumor growth fraction (Ki67 Li) J Urol 153 (4):535

    Google Scholar 

  • Ghazizadeh M, Yamamoto S, Kurokawa K (1983) Clinical features of urachal carcinoma in Japan: review of 157 patients. Urol Res 235

    Article  CAS  PubMed  Google Scholar 

  • Ghonheim MA, Ashamallah AK, Awaad HK, Whitemore WF Jr (1985) Randomized trial of cystectomy with or without preoperative randiotherapy for carcinoma of the bilharzial bladder. J Urol 134:266

    Google Scholar 

  • Glashan RW (1990) A randomized eontrolled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144:658

    CAS  PubMed  Google Scholar 

  • Glick SH, Meyers F, White RW (1995) Relationship of p53 and BCL-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 153 (4): 539

    Google Scholar 

  • Goepel M, Rubben H (1991) TNM-orientierte Therapieplanung beim Harnblasenkarzinom. Urologe A 30:151

    CAS  PubMed  Google Scholar 

  • Goldfarb A, Pasccon G, Koliren L et al. (1990) Methotrexate, vindesine, epidocorubicin, and cisplatin (M-VEC) for stage III-IV bladder cancer (meeting abstract). Proc Annu Meet Am Soc Oncol 9:A 593

    Google Scholar 

  • Gonwa TA, Corbett WT, Schey HM, Buckalew VM (1980) Analgesic associated nephropathy and transitional cell carcinoma of the urinary tract. Ann Intern Med 93:249

    CAS  PubMed  Google Scholar 

  • Goodman GB, Hislop TG, Elwood IM, Balfour J (1981) Conservation of bladder function in patients with invasive bladder cancer treated by definitive irradiation and selective cystectomy. Int R Radiat Oncol Biol Phys 7:569

    Article  CAS  Google Scholar 

  • Green DF, Robinson MRG, Glashan R, Newling D, Dalesio O, Smith PH (1984) Does intravesical chemotherapy prevent invasive bladder cancer. J Urol 131:33

    CAS  PubMed  Google Scholar 

  • Guirguis R (1988) Detection of autocrine motility factor in urine as a marker of bladder cancer. JNCI 80/15: 1203–1211

    Article  CAS  PubMed  Google Scholar 

  • Haaff EO, Dresner SM, Ratliff TL (1986) Two courses of intravesical bacillus calmette-guérin for transitional cell carcinoma of the bladder. J Urol 136:820

    CAS  PubMed  Google Scholar 

  • Hall RR, Newling DWW, Ramsden PD, Richards B, Robinson MRG, Smith PH (1984) Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 56:668

    Article  CAS  PubMed  Google Scholar 

  • Hall RR, Roberts T, Powell PH, Marsh MM (1988) TUR and chemotherapy or radiotherapy for invasive bladder cancer. Prog Clin Biol Res 260:605

    CAS  PubMed  Google Scholar 

  • Hara M (1989) Fundamental studies on intravesical instillation of interferons for treatment of bladder cancer. Jpn J Urol 80:158

    CAS  Google Scholar 

  • Hansen AB, Bjerregaard B, Ovesen H, Horn T (1992) AgNOR counts and histological grade in stage pTa bladder tumors: reproducibility and relation to recurrence pattern. Histopathology 20 (3): 257–262

    Article  CAS  PubMed  Google Scholar 

  • Hecht SS, Tso TC, Hoffmann D (1976) Selective reduction of tumorgenicity of tobacco smoke. IV Approaches to the reduction of N-nitrosamines and aromatic amines. Proceedings of Third World Conference on smoking and health. Dept Health Education and Welfare Publ No (NIH) 76:535

    Google Scholar 

  • Heicappell R, Sartorius S, Miller K (1995) Loss of E- and N-cadherins in advanced renal cell carcinoma (RCC). J Urol 153 (4): 635

    Google Scholar 

  • Henry K, Miller J, Mori M, Loening S, Fallon B (1988) Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140:964

    CAS  PubMed  Google Scholar 

  • Herr HW (1987) Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 138:1162

    CAS  PubMed  Google Scholar 

  • Herr HW, Whitemore WF Jr (1987) Ureteral carcinoma in situ after successful intravesical therapy for superficial bladder tumors: incidence, possible pathogenesis and management. J Urol 138:292

    CAS  PubMed  Google Scholar 

  • Herr HW, Pinsky CM, Whitemore WF, Oettgen HF, Melamed MR (1983) Intravesical BCG therapy of superficial bladder tumors. In: Proceedings of the 78th Annual Meeting of the American Urological Association, Las Vegas, Nevada, 19. April

    Google Scholar 

  • Herr HW, Laudone VP, Badalament RA et al. (1988) Bacillus calmette-guérin therapy alters in progression of superficial bladder cancer. J Clin Oncol 6/9:1450–1456

    CAS  PubMed  Google Scholar 

  • Herr WW, Whitemore WF Jr, Morse MJ, Sogani PC, Russo P, Fair WR (1990) Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. J Urol 144:1083

    CAS  PubMed  Google Scholar 

  • Hicks RM, Chowaniec J (1978) Experimental induction, histology and ultrastructure of hyperplasia and neoplasia of the urinary bladder epithelium. Int Rev Exp Pathol 18:199

    CAS  PubMed  Google Scholar 

  • Hicks RM, Wakefield JSJ (1972) Rapid induction of bladder cancer in rats with NMNU. Chem Biol Interact 5:139

    Article  CAS  PubMed  Google Scholar 

  • Hicks RM, Wakefield JSJ (1973) Bladder cancer and NMNU. Chem Biol Interact 7:165

    Article  PubMed  Google Scholar 

  • Hicks RM, Wakefield JSJ (1976) Membrane changes during urothelial hyperplasia and neoplasia. Cancer Res 36:2502

    CAS  PubMed  Google Scholar 

  • Hicks RM, Walters CL, El Sebai I, El Asser AB, El Merzabani M, Grough TA (1977) Demonstration of nitro-samines in human urine. Preliminary observations on a possible aetiology for bladder cancer in association with chronic urinary tract infection. Proc R Soc Med 70:413

    CAS  PubMed  Google Scholar 

  • Higby DJ (1980) Chemotherapeutic management of bladder cancer. In: Aisner J, Chang P (eds) Cancer treatment research. Developments in oncology series, vol 2. Nijhoff, The Hague, pp 142

    Chapter  Google Scholar 

  • Hijazi A, Devonec M, Bouvier R, Revillard J-P (1989) Flow cytometry study of cytokeratin 18 expression according to tumorgrade and desoxyribonucleic and content in human bladder tumors. J Urol 141: 522–526

    CAS  PubMed  Google Scholar 

  • Hillcoat BL, Raghavan D, Matthews J et al. (1989) A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of urothelial tract. J Clin Oncol 7:706

    CAS  PubMed  Google Scholar 

  • Hoffmann D, Masuda Y, Wynder EL (1969) Alpha-naphthylamine and beta-naphthylamine in cigarette smoke. Nature 221:254

    Article  CAS  Google Scholar 

  • Hudson MA, Nadler RB, Swanson PE, Humphrey PA (1995) P53 protein accumulation in superficial bladder cancer: a predictor of tumor progression which is not affected by intravesical BCG therapy. J Urol 153 (4):531

    Google Scholar 

  • Hueper WC, Wiley FH, Wolfe HD (1938) Experimental production or bladder tumours in dogs by administration of beta-naphthylamine. J Indust Hyg Toxicol 20/1:46

    CAS  Google Scholar 

  • Huh NH, Rajewsky MF (1986) Enzymatic elimination of OG-ethylguanine and stability of 04-ethylthymine in the DNA of malignant neural cell lines exposed to NMNU in culture. Carcinogenesis 7/3:435

    Article  CAS  PubMed  Google Scholar 

  • Huh NH, Rajewsky MF (1988) Enzymatic elimination of OG-ethylguanine from the DNA of MNU exposed normal and malignant rat brain cells grown under cell culture versus in vivo conditions. Int J Cancer 41/5:762

    Article  CAS  PubMed  Google Scholar 

  • Huland H, Otto U, Dröse M, Klöppel G (1984) Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol 132:27

    CAS  PubMed  Google Scholar 

  • Huland H, Klöppel G, Otto U et al. (1990) Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma. First evaluation of a prospective multicenter study with 419 patients. J Urol 144:68

    CAS  PubMed  Google Scholar 

  • Huland E, Huland H, Schneider AW (1990) Quantitative immunocytology in the management of patients with superficial bladder carcinoma. A marker to identify patients, who do not require prophylaxis. J Urol 144:637–641

    CAS  PubMed  Google Scholar 

  • Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T (1990) Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144:662

    CAS  PubMed  Google Scholar 

  • Irving CC, Murphy WM, Damil DS (1984) Comparative carinogenicity of N-Butyl-N-(3 carboxypropyl)-Nitrosamin and N-Butyl-N-(4 hydroxybutyl) nitrosamine for the urinary bladder of (C5BL/6xDBA/2)F1 mice. JNCI 73/3:753–756

    CAS  PubMed  Google Scholar 

  • Ito N (1984) Histogenesis of urinary bladder tumors induced by nitrosamine in rats. J Cancer Res Clin Oncol 108:169–173

    Article  CAS  PubMed  Google Scholar 

  • Ito N (1988) Early changes caused by nitrosamine in the bladder epithelium of different animal species. Jpn J Cancer Res 79 (4): 413–417

    Article  CAS  PubMed  Google Scholar 

  • Jaeger TM, Weidner N, Carroll PR (1994) Tumor angiogenesis and lymph node metastasis in invasive bladder carcinoma. Urol 151 (5): 482–489

    Google Scholar 

  • Jakse G, Schneider H-M, Jacobi GH (1978) Urachal signet-ring cell carcinoma, a rare variant of vesical adenocarcinoma: incidence and pathological criteria. J Urol 120:764–766

    CAS  PubMed  Google Scholar 

  • Jakse G, Hofstädter F (1980) Intravesical doxorubicin hydrochloride in the management of carcinoma in situ of the bladder. Eur Urol 6:103

    CAS  PubMed  Google Scholar 

  • Jakse G, Jacobi GH, Altwein JE (1979) Das Adenokarzinom der Harnblase. Urologe A 18:86

    CAS  PubMed  Google Scholar 

  • Jakse G, Hofstädter F, Marberger H (1984) Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a follow-up. J Urol 131:41

    CAS  PubMed  Google Scholar 

  • Jauhiainen K, Rintala E, Alfthan O (1988) XXX. Congress of the International Society of Urology, Buenos Aires, Argentina

    Google Scholar 

  • Jauhiainen K, Rintala E, Alfthan O, Finnbladder Group (1990) Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial bladder cancer. In: Kernion JE de (ed) International Society of urology reports, — immunotherapy of urological tumors, vol 2. Churchill Livingstone, Endin-burgh, p 13

    Google Scholar 

  • Jenkins BJ, Caulfield MJ, Fowler CG (1988) Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 62:343

    Article  CAS  PubMed  Google Scholar 

  • Jewett HJ, King LR, Shelley WM (1964) A study of 365 cases of infiltrating bladder cancer: relation of certain pathological characteristics to prognosis after extirpation. J Urol 92:668

    CAS  PubMed  Google Scholar 

  • Johnson DE, Schoenwald MB, Ayala AG, Miller LS (1976) Squamous cell carcinoma of the bladder. J Urol 115:542

    CAS  PubMed  Google Scholar 

  • Jouanneau J, Gavrilowic J, Cavuelle D et al. (1991) Secreted or non-secreted forms of acid fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility and invasive potential. Proc Natl Acad Sci USA 88:2893–2897

    Article  CAS  PubMed  Google Scholar 

  • Jurincic C, Engelmann U, Gasch J, Klippel KF (1988) Immunotherapy in bladder cancer with keyhole limpet haemocyanin: a prospective randomized trial. J Urol 139:723

    CAS  PubMed  Google Scholar 

  • Jurincic C, Stöcker W, Markl J, Engelmann U, Gasch J, Klippel KF (1990) Immunotherapy with keyhole limpet haemocyanin (KLH) as prophylaxis against superficial bladder tumor recurrence. In: Kernion JB De (ed) Immunotherapy of urological tumors. Churchill Livingstone, London, p 139

    Google Scholar 

  • Kadlubar FF, Miller JA, Miller EC (1978) Guanyl O6-arylamination and O6-arylation of DNA by the carcinogen N-hydroxy-1-naphthylamine. Cancer Res 38:3628

    CAS  PubMed  Google Scholar 

  • Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM (1991) Stage T1 bladder cancer grade is the primary determinant for risk of muscle invasion. J Urol 146:28

    CAS  PubMed  Google Scholar 

  • Kaufman JM, Farn B, Jacobs SC, Gabrilondo F, Yalla S, Kane JP, Rossier AB (1977) Bladder cancer and squamous metaplasia in spinal cord injury patients. J Urol 118:967

    CAS  PubMed  Google Scholar 

  • Kavoussi LR, Torrence RJ, Gillen DP et al. (1988) Results of 6 weekly intravesical bacillus calmette-guérin instillations on the treatment of superficial bladder tumors. J Urol 139:935

    CAS  PubMed  Google Scholar 

  • Kaye SB, MacDougall RH, Simonds RP, Tolley DA (1988) The management of bladder cancer in Scotland. In: Raghaven D (ed) The management of bladder cancer. Arnold, London pp 264–276

    Google Scholar 

  • Kernion JB de, Huang MY, Lindern A (1985) The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus calmette-guérin. J Urol 133:598

    Google Scholar 

  • Khandekar JD, Elson PJ, Wys WD de, Slayton RE, Harris DT (1985) Comparative activity and toxicity of cis-diaminedichloroplatinum in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539

    CAS  PubMed  Google Scholar 

  • Kim HH, Lee C (1989) Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J Urol 141:1337

    CAS  PubMed  Google Scholar 

  • Koch PJ, Walsh MJ, Schmelz M, Goldschmidt MD, Zimbelman R, Franke WWS (1990) Identification of desmoglein, a constitutive desmosomal glycoprotein as a member of the Cadherin family of cell adhesin molecules. Eur J Cell Biol 54:1–12

    Google Scholar 

  • Koontz WW Jr, Prout GR, Smith W, Frables WJ, Minnis JE (1981) The use of intravesical thiotepa in the management of non-invasive carcinoma of the bladder. J Urol 125:307

    PubMed  Google Scholar 

  • Koss LG, Melamed MR, Ricci A, Melick WF, Kelly RE (1964) Carcinogenesis in the human urinary bladder. Engl J Med 272:767

    Article  Google Scholar 

  • Kramer SA, Bredael J, Croker BP (1979) Primary nonurachal adenocarcinoma of the bladder. J Urol 121: 278–282

    CAS  PubMed  Google Scholar 

  • Krege S, Otto T, Rübben H (1995) Adjuvante Therapie bei oberflächlichem Urothelkarzinom der Harnblase. Urol [A] Suppl 1:17

    Google Scholar 

  • Kriegmair M, Waidelich R, Lumper W, Ehsan A, Baumgartner R, Hofstetter A (1995) Integral photodynamic treatment of refractory superficial bladder cancer. J Urol 154 (4): 1339–1341

    Article  CAS  PubMed  Google Scholar 

  • Kuczyk MA, Serth J, Allhoff EP, Jonas U (1993) Das p53-Tumorsuppressorgen als neuer Prognosefaktor für den klinischen Verlauf von Harnblasenkarzinomen. In: Klapdor R (ed) Current tumor diagnosis: applications, clinical relevance, researchtrends, Zuckschwerdt, München, Bern, Wien, New York, p 177

    Google Scholar 

  • Kunze E, Calude J, Frentzel-Beyme R (1986) Associalion of cancer ot the lower urinary tract with consumption of alcoholic beverages — a case control study. Carcinogenesis 7:163

    Article  CAS  PubMed  Google Scholar 

  • Kurth KH, Schröder FH, Tunn U et al. (1984) Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research of treatment of cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J Urol 132:258

    CAS  PubMed  Google Scholar 

  • Kurth KH, Debruyne FJM, Senge T, Carpentier PJ, Riedl H, Sylvester R, Pauw M de (1985) Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trial comparing doxorubicin hydrochloride, ethoglucid and TUR-alone. Prog Clin Ciol Res 162A: 135

    Google Scholar 

  • Kurth KH, Bouffioux C, Sylvester R, Pauw M de, and members of the EORTC GU Group (1988) Early and delayed instillation with and without maintenance of either adriamycin or mitomycin C in patients with superficial transitional carcinoma of the bladder. In: Di Silverio F, Steg A (eds) International workshops in urology, new trends in bladder cancer chemotherapy, new trends in BPH etiopathogenesis. Acta Medica, Cannes, p 159

    Google Scholar 

  • Kurth KH, Sylvester R, Pauw M de, ten Kate F (1989) Intracavitary treatment of transitional cell carcinoma of the bladder questions and lessons after 27 years of experience. Prog Clin Biol Res 310:125

    CAS  PubMed  Google Scholar 

  • Laerum OD, Rajewsky MF (1975) Neoplastic transformation of fetal rat brain cells in culture after exposure to ENU in vivo. J Natl Cancer Inst 55:5

    Google Scholar 

  • Lamm DL (1985 a) BCG versus adriamycin in bladder cancer: a southwest oncology group study. Proceedings of ASCO

    Google Scholar 

  • Lamm DL (1985 b) Bacillus calmette-guérin immunotherapy for bladder cancer. J Urol 134:40

    CAS  PubMed  Google Scholar 

  • Lamm DL (1985 c) BCG vs. adriamycin in the treatment of transitional cell carcinoma in situ — a southwest oncology group study. J Urol [A] 133:283

    Google Scholar 

  • Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19/3:573–580

    CAS  PubMed  Google Scholar 

  • Lamm DL, Crissman J, Blumenstein B (1989) Adriamycin versus BCG in superficial bladder cancer: a SWOG study. Prog Clin Biol Res 310:263

    CAS  PubMed  Google Scholar 

  • Laplante M, Brice MH (1973) The upper limits of hopeful application of radical cystectomy for vesical carcinoma: does nodal metastasis always indicate incurability? J Urol 109:261

    CAS  PubMed  Google Scholar 

  • Linn JFJ, Rübben H (1995) Die Wirkung von Keyhole-Limpet-Haemocyanin auf chemisch induzierte Blasentumore bei Ratten. Vergleich subkutaner vs. intravesikaler Applikation vs. Kontrollgruppe. 12. Symposium für experimentelle Urologie. 18.03.95, Berlin.

    Google Scholar 

  • Lipponen PK, Eskelinen MJ, Nordling S (1991) Nucleolar organizer regions (AgNORs) as predictors in transitional cell bladder cancer. Br J Cancer 64:1139–1144

    Article  CAS  PubMed  Google Scholar 

  • Lipponen PK, Eskelinen MJ (1995) Reduced expression of E-cadherin isrelated to invasive deisease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121 (5): 303–308

    Article  CAS  PubMed  Google Scholar 

  • Llopis B, Gallego J, Mompo JA, Boronat F, Jimenez JB (1985) Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors. Eur Urol 11:73

    CAS  PubMed  Google Scholar 

  • Loehrer PJ, Elson P, Kuebler JP et al. (1990) Advanced bladder cancer: a prospective intergroup trial comparing single agent cisplatin (CDDP) vs M-VAC combination therapy (INT 0078) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 9: A511

    Google Scholar 

  • Logothetis CJ, Johnson DE, Cong C et al. (1988) Adjuvant cyclosphosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer an update. J Clin Oncol 6:1590

    CAS  PubMed  Google Scholar 

  • Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S (1989) Cisplatin, cyclophosphamid and doxorubicin chemotherapy for unresectable urothelial tumors: The M.D. Anderson experience. J Urol 141:33

    CAS  PubMed  Google Scholar 

  • Logothetis JC, Dexeus FH, Fin L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8/6:1050

    CAS  PubMed  Google Scholar 

  • Lower GM (1982) Concepts in causality: chemically induced human bladder cancer. Cancer 49:1056

    Article  CAS  PubMed  Google Scholar 

  • Madsen PO, Hoyme UB, Byar DP, VA Cooperative Research Group (1980) Paper presented to the North Central survival rates in three bladder cancer groups. Urol Times, p 20, April

    Google Scholar 

  • Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG (1990) The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 144: 641

    CAS  PubMed  Google Scholar 

  • Malmström P-U, Busch C, Norlén BJ (1987) Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol 21:185

    Article  PubMed  Google Scholar 

  • Mareel MM (1983) Invasion in vitro: Methods of analysis. Canncer Metastasis Rev 2:201–218

    Article  CAS  Google Scholar 

  • Marshall VF, McCarron JP Jr (1977) The curability of vesical cancer: greater now or then? Cancer Res 37: 2753

    CAS  PubMed  Google Scholar 

  • Marth D, Studer UE, Ackermann D, Zingg EJ (1991) Primäre Therapieversager nach intravesikalem BCG wegen Carcinoma in situ erlauben kein exspektatives Verhalten. Urologe A [Suppl] 30:71

    Google Scholar 

  • Martinez-Pineiro JA, Arocena F, Escudero A et al. (1990 a) Neoadjuvant cisplatinum for locally advanced TCC of the urinary bladder: a prospective study of the Cueto Group (meeting abstract). Eur Urol 18 [Suppl 1]:149

    Google Scholar 

  • Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro et al. (1990 b) Bacillus calmette-guérin versus doxorubicin versus thiotepa instillation for primary superficial bladder cancer. Interim report of a randomized prospective study. In: Kernion JE de (ed) Immunotherapy of urological tumors. Churchill Livingston, London, p 59

    Google Scholar 

  • Martinez-Pineiro JA, Jemenez Leon J, Martinez-Pineiro L Jr (1990 c) Bacillus calmette-guérin versus doxorubicin versus thiotepa: a randomized study in 202 patients with superficial bladder cancer. J Urol 143:502

    CAS  PubMed  Google Scholar 

  • Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. (1995) Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 153:964–973

    Article  CAS  PubMed  Google Scholar 

  • Martinez-Pineiro JA, Solsona E, Flores N, Isorna S (1995) Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO. Eur Urol 27 [Suppl 1]: 13–18

    PubMed  Google Scholar 

  • Masters JRW, Camplejohn RS, Parkinson MC, Woodhouse CRI (1985) DNA ploidy and the prognosis of stage pTi bladder cancer. Br J Urol 64:403–108

    Article  Google Scholar 

  • Masters JRW, Vesey SG, Munn CF, Evan GI, Watson JV (1988) C-myc oncoprotein levels in bladder cancer. Urol Res 16:341

    Article  CAS  PubMed  Google Scholar 

  • Mathur VK, Krahn HP, Ramsey EW (1981) Total cystectomy for bladder cancer. J Urol 125:784

    CAS  PubMed  Google Scholar 

  • Mechanic S, Raynor K, Hill JE, Cowin P (1991) Desmocollins form a distinct subset of the Cadherin family of cell adhesion molecules. Proc Natl Acad Sci USA 88:4476–4480

    Article  CAS  PubMed  Google Scholar 

  • Melick WF, Naryka JJ, Kelly RE (1971) Bladder cancer due to exposure to para-aminobiphenyl: a 17 year follow up. J Urol 106:220

    CAS  PubMed  Google Scholar 

  • Miller LS (1977) Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39:973

    Article  CAS  PubMed  Google Scholar 

  • Milner WA (1954) The role of conservative surgery in the treatment of bladder tumors. Br J Urol 26:375

    Article  CAS  PubMed  Google Scholar 

  • Mishina T, Oda K, Murata S, Ooe H, Mori Y, Takahashi T (1975) Mitomycin C bladder instillation therapy for bladder tumors. J Urol 114:217

    CAS  PubMed  Google Scholar 

  • Montie JE, Straffon RA, Stewart BH (1984) Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol 131:477

    CAS  PubMed  Google Scholar 

  • Moon WC, Lee CY, Kim YS (1995) Expression of vascular endothelial growth factor and basic fibroblast growth factor in renal cell carcinoma. J Urol 153 (4): 630

    Google Scholar 

  • Morales A, Ottenhof P, Emerson L (1981) Treatment of residual, non-infiltrating bladder cancer with bacillus calmette-guérin. J Urol 125:649

    CAS  PubMed  Google Scholar 

  • Mori K, Lamm DL, Crawford ED (1986) A trial of bacillus calmette-guérin versus adriamycin in superficial bladder cancer: a south-west oncology group study. Urol In 322:1

    Google Scholar 

  • Morrison AS, Cole P (1976) Epidemiology of bladder cancer. Urol Clin North Am 3:13

    CAS  PubMed  Google Scholar 

  • Morrison AS, Cole P (1982) Urinary tract. In: Schottenfeld D, Fraumeni FJ, Saunders WB (eds) Cancer epidemiology and prevention. Saunders, Philadelphia, p 925

    Google Scholar 

  • Morrison R (1975) The results of radiation treatment of cancer of the bladder: clinical contribution of radio-biology. Clin Radiol 76:67

    Article  Google Scholar 

  • Mostofi FK, Thompson RV, Dean AL (1955) Mucous adenocarcinoma of urinary bladder. Cancer 8:741–749

    Article  CAS  PubMed  Google Scholar 

  • MRC Working Party on Urological Cancer, London (1985) The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC study. Br J Urol 57:680

    Article  Google Scholar 

  • Mulder PH de, Debruyne FM, Keizer HJ, Ten Bokkel Huinick W, Pauw M de, Sylvester R (1990) Randomized phase II study of methotrexate (M), cisplatin (C) and methotrexate, cisplatin and vinblastine (V) in patients with advanced transitional carcinoma of the bladder (Meeting Abstract) Eur Urol 18 [Suppl 1]1: 5

    Google Scholar 

  • Mulder AH, Hootegem JCSP van, Sylvester R et al. (1992) Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki67). J Pathol 66:37–43

    Article  Google Scholar 

  • Mulder AH, Van Hootegem JCSP, Sylvester R, Tenn Kate FJW, Kurth KH, Ooms ECM, Vand der Kwast RTH (1992) Prognostic factors in Bladder Carcinoma: histologic parameters and expression of a cell cyclerelated nucelar antigen (Ki67). J Pathol 66:37–43

    Article  Google Scholar 

  • Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K, Takkeichi M (1987) Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature (London) 329:241–243

    Article  Google Scholar 

  • Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW (1981) Methotrexate: an active drug in bladder cancer. Cancer 17:1246

    Article  Google Scholar 

  • Neal DE, Smith K, Fennelly IA, Bennett MK, Hall Reg R, Harris AL (1989) Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. J Urol 141:517

    CAS  PubMed  Google Scholar 

  • Netto NR Jr, D’Ancona CAL (1990) Bacillus calmette-guérin immunotherapy in bladder cancer. In: Kernion JB de (ed) Immunotherapy of urological tumors. Churchill Livingstone, London, p 3

    Google Scholar 

  • Nicolas V, Harder T, Steudel A, Krahe T, Schindler G, Van Ahlen H, Jaeger N (1988) Die Wertigkeit bildgebender Verfahren bei der Diagnostik und dem Staging von Harnblasentumoren. ROFO 148:234

    Article  CAS  PubMed  Google Scholar 

  • Niijima T, Koiso K, Akaza H (1983 a) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11:79

    Article  CAS  PubMed  Google Scholar 

  • Niijima T, Koiso K, Akaza H (1983) Randomized clinical trial for chemoprophylaxis of recurrence in superficial bladder cancer. In: Spitzy KH, Karrer K (eds) Proceedings of the 13th International Congress of Chemotherapy, Vienna, pp 240/6–240/8

    Google Scholar 

  • Norming U, Trubikait B, Gustafson H, Nyman CR, Wang N, Wijkström H (1992) Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J Urol 147:11

    CAS  PubMed  Google Scholar 

  • Norpoth K, Woitowitz HJ (1994) Beruflich verursachte Tumoren. Dtärzte Verlag, Köln, S 25–31

    Google Scholar 

  • Ohkawa T, Fujinaga T, Doi J, Ebisuno S, Takamatsu M, Nakamura J, Kido R (1982) Clinical study on occupational uroepithelial cancer in Wakayama City. J Urol 128:520

    CAS  PubMed  Google Scholar 

  • Ohtani M, Tukushima S, Okamura T, Sadata T, Ito N, Koiso K, Niijima T (1984) Effects of intravesical instillation of antitumor chemotherapeutic agents on bladder carcinogenesis in rats treated with N-butyl-N-(hydroxybutyl) nitrosamine. Cancer 54:1525–1529

    Article  CAS  PubMed  Google Scholar 

  • Olson CA, Vere White RW de (1979) Cancer of the bladder. In: Javadpour N (ed) Principles and management of urologic cancer. Williams & Wilkins, Baltimore, p 337

    Google Scholar 

  • Otto T, Rübben H (1991) Das Carcinoma in situ der Harnblase — Definition und Stand der Behandlung. Urologe A 30:163

    CAS  PubMed  Google Scholar 

  • Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, Rübben H (1992) E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol Res 21:329–362

    Google Scholar 

  • Otto T, Birchmeier W, Schmidt U, Hinke A, Schipper J, Rübben H, Raz A (1994) Inverse relation of E-Cad-herin and autocrine motility factor receptor expression as prognostic factors in patients with bladder carcinoma. Cancer Res 54:3120–3123

    CAS  PubMed  Google Scholar 

  • Otto T, Steinberg F, Goepel M, Rübben H (1994) Kapillardichte bei Harnblasenkarzinomen und normalem Urothel. Urol [A] S1:107

    Google Scholar 

  • özkardes H, Ergen A, Ozen HA, Ayhan A, Remzi LD, Tasar C (1990) Immunohistochemical detection of beta-human chorionic gonadotropin in urothelial tumors. EUA Meeting (Abstr) 156

    Google Scholar 

  • Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milanni C (1995) Improving the efficacy of BCG immunotherapy by dose reduction. Eur. Urol 27 [Suppl 1]: 19–22

    PubMed  Google Scholar 

  • Patrianakos C, Hoffman D (1979) Chemical studies on tobacco smoke. LXIV On the analysis of aromatic amines in cigarette smoke. J Anal Toxicol 3:150

    CAS  Google Scholar 

  • Patterson JM, Ray EH Jr, Mendiondo OA, Medina WD, Gee WF (1988) A new treatment for invasive squamous cell bladder cancer: the nigro regimen: preoperative chemotherapy and radiation therapy. J Urol 140:379

    CAS  PubMed  Google Scholar 

  • Pauwels RP, Smeets WW, Geraedts JP, Debruyne FM (1987) Cytogenetic analysis in urothelial cell carcinoma. J Urol 137:210–215

    CAS  PubMed  Google Scholar 

  • Pearse HD, Reed RR, Hodges CV (1978) Radical cystectomy for bladder cancer. J Urol 119:216

    CAS  PubMed  Google Scholar 

  • Pearson RM, Soloway MS (1978) Does cyclophosphamide induce bladder cancer? Urology 4:437

    Article  Google Scholar 

  • Petkovic S, Multavdzic M, Petronic V, Marcovic V (1971) Tumours of the renal pelvis and ureter: clinical and aetiologic studies. J Urol Nephrol (Paris) 77:429

    CAS  Google Scholar 

  • Pinsky CM, Camacho FJ, Kerr D et al. (1985) Intravesical administration of bacillus Calmette-Guérin in patients with recurrent carcinoma of the urinary bladder: report of a prospective, randomized trial cancer treatment. Report 69:1

    Google Scholar 

  • Popov Z, Diez SG, Hoznek A, Radvayi F, Bellot J, Abbou CCI, Chopin D (1995) Decreased E-cadherin expression by immunohistochemistry is strongly correlated with stage and grade in bladder cancer. J Urol 153 (4):1182

    Article  Google Scholar 

  • Pritchett TR, Schiff WM, Klatt E, Lieskovsky G, Skinner DG (1988) The potency-sparing radical cystectomy: does it compromise the completeness of the cancer resection? J Urol 140:1400

    CAS  PubMed  Google Scholar 

  • Prout GR (1976) The surgical management of bladder carcinoma. Urol Clin North Am 3:149

    PubMed  Google Scholar 

  • Prout GR Jr, Koontz WW Jr, Coombs LJ, Hawkins IR, Friedeil GH for National Bladder Cancer Collaborative Group (1983) A long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 130:677

    PubMed  Google Scholar 

  • Prout GR Jr, Griffm PP, Daly JJ (1987) The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 138:766–770

    PubMed  Google Scholar 

  • Quilty PM, Duncan W (1986) Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 12:853

    Article  CAS  PubMed  Google Scholar 

  • Radomski JL, Brill E (1970) Bladder cancer induction by aromatic amines: role of N-hydroxy metabolites. Science 167:992

    Article  CAS  PubMed  Google Scholar 

  • Raghavan D, Pearson B, Duval P et al. (1985) Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer? J Urol 133:399

    CAS  PubMed  Google Scholar 

  • Raghavan D, Wallace DMA, Sandeman T (1989) First randomized trials of pre-emptive (neoadjuvant) intravenous (IV) cisplatin (CDDP) for invasive transitional cell carcinoma of the bladder (TCCB) (Abstract). Proc Am Soc Clin Oncol 8:133

    Google Scholar 

  • Rajewsky MF, Adamkiewicz J, Eberle B, Huh N, Nehls P, Thomale J (1986) Prog Clin Biol Res 209A: 199

    CAS  PubMed  Google Scholar 

  • Ramaekers F, Huysmans A, Moesker O, Schaart G, Herman C, Vooijs P (1985) Cytokeratin expression during neoplastic progression of human transitional cell carcinoma as detected by a monoclonal and a polyclonal antibody. Lab Invest 52:31

    CAS  PubMed  Google Scholar 

  • Ratko TA et al. (1990) Effect of BBN in different mice strains. Anticancer Res 10 (1): 67–72

    CAS  PubMed  Google Scholar 

  • Recker F, Otto T (1991) Tierexperimentelle Aspekte des Blasenkarzinoms, Urologe [A] 30:172–179

    CAS  Google Scholar 

  • Rehn L (1895) Blasengeschwülste bei Fuchsinarbeitern. Arch Klin Chir 50:588

    Google Scholar 

  • Richards B (1980) Adjuvant chemotherapy following primary irradiation in T3 tumors, and other topics in urological oncology. In: Pavone Macaluso M, Smith PH, Edsmyr F (eds) Bladder tumors and other topics in urological oncology. Plenum, New York, pp 395

    Google Scholar 

  • Riddle PR, Wallace DM (1971) Intracavity chemotherapy for multiple non-invasive bladder tumors. Br J Urol 43:181

    Article  CAS  PubMed  Google Scholar 

  • Riddle PR, Chisholm GD, Trott PA, Pugh RCB (1976) Flat carcinoma in situ of the bladder. Br J Urol 47: 825

    Google Scholar 

  • Ringwald M, Schuh R, Vestweber D et al. (1987) The structure of the cell adhesion molecular uvomorulin. Insights into the molecular mechanism of Ca2+-dependent cell adhesion. EMBO J 6:3647–3653

    CAS  PubMed  Google Scholar 

  • Roberts JT, Fossa SD, Richards B et al. (1991) Results of medical research council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder. Br J Urol 68:162

    Article  CAS  PubMed  Google Scholar 

  • Roehrborn CG, Sagalowsky AI, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146:36

    CAS  PubMed  Google Scholar 

  • Rose MA, Shipley WU, Perrone T (1983) Definitive radiation for patients with invasive bladder carcinoma: results and prognostic factors. Proceedings of the 25th Annual ASTRO Meeting. Int J Radiat Oncol Biol Phys [Suppl 1] 9:73

    Google Scholar 

  • Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 153:894–900

    Article  CAS  PubMed  Google Scholar 

  • Roth BJ (1995) Preliminary experience with paclitaxel in advanced bladder cancer. Sem Oncol 22 [Suppl 6]:1–5

    Google Scholar 

  • Rübben H (1988) Kommentar: Chemoprophylaxe beim superficialen Blasenkarzinom 1988. Urologe A 27: 152

    PubMed  Google Scholar 

  • Rübben H, Jocham D (1991) Therapie des oberflächlichen Blasenkarzinoms. Urologe A 30:2

    PubMed  Google Scholar 

  • Rübben H, Lutzeyer W, Ebbinghaus KD, Dahm HH (1984) Adjuvant radiotherapy in Ta, T1 and T2 bladder tumors after transurethral resection: a retrospective study. In: Wallace DMA (ed) Bladder cancer, part B: radiation, local and systemic chemotherapy and new treatment modalities, A.R. Liss, New York, pp 21–21

    Google Scholar 

  • Rübben H, Lutzeyer W, Fischer N, Deutz F-J, Lagrange W, Giani G and Members of the Registry for Urinary Tract Tumors, Rheinisch Westfälische Technische Hochschule Aachen (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283

    PubMed  Google Scholar 

  • Rübben H, Weißbach L, Knebel L, Deutz F-J, Giani G, Grad-Dobberstein C, Gebhard R (1990) Adjuvant systemic chemotherapy after complete transurethral resection of superficially invasive bladder carcinoma. Urol Int 45:78

    Article  PubMed  Google Scholar 

  • Rubin P (1975) Radiation biology and pathology syllabus. Am College of Radiology, Chicago.

    Google Scholar 

  • RUTT (Registry for Urinary Tract Tumors) (1985) Harnwegstumorregister. Jahresbericht. Verh Dtsch Ges Urol 37:665

    Google Scholar 

  • Saito B et al. (1990) Chemical induced bladder carcinoma in mice. Nippon Hinyokikka Gakka Zasshi 81 (7): 993–996

    CAS  Google Scholar 

  • Sarosdy M (1995) Results of a multicenter trial using BTA test to monitor and diagnose recurrent bladder cancer. J Urol 153:14

    Article  Google Scholar 

  • Sarosdy MF, Lamm DL (1989) Long-term results of intravesical bacillus calmette-guérin therapy for superficial bladder cancer. J Urol 142:719

    CAS  PubMed  Google Scholar 

  • Sattler TA, Dimitrov T, Hall PW (1977) Relation between endemic (Balkan) nephropathy and urinary tract tumours. Lancet 2:278

    Article  Google Scholar 

  • Sauer R, Dunst I, Altendorf-Hofmann A (1990) Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 19:687

    Article  CAS  PubMed  Google Scholar 

  • Schellhammer PF, Whitmore WF Jr (1976) Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 115:56

    CAS  PubMed  Google Scholar 

  • Scher HI, Yagoda A, Herr HW (1988) Neo-adjuvant M-VAC (methorexate, vinblastine, doxorubicin and cisplatin): effect on the primary bladder lesion. J Urol 139:470

    CAS  PubMed  Google Scholar 

  • Schipper JH, Frixen UH, Behrens J, Unger A, Jahncke K, Birchmeier W (1991) E-cadherin expression in squamous cell carcinomas of head and neck: Inverse correlation with tumor differentiation and lymph node metastasis. Cancer Res 51:6328–6337

    CAS  PubMed  Google Scholar 

  • Schmitz-Dräger BJ, Ebert T, Ackermann R (1986) Intravesical treatment of superficial bladder carcinoma with interferons. World J Urol 3:218

    Article  Google Scholar 

  • Schmitz-Dräger B, Strick JWE, Gerke R, Decken K, Ebert T (1995) Filterimmuncytologic (FLIC) — Klinische Ergebnisse und Entwicklung einer neuartigen Technik. Akt Urol 1:90–93

    Article  Google Scholar 

  • Schnyder von Wartensee M, Ackermann D, Studer UE, Zingg EJ (1989) Die Behandlung des Carcinoma in situ der Harnblase mit BCG. Helv Chir Acta 56:351

    Google Scholar 

  • Schulmann CC, Rozencweig M, Staquet M, Kenis Y, Sylvester R (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, VM-26 and TUR alone. Eur Urol 8:207

    Google Scholar 

  • Schulte PA, Ringen K, Hemstreet GP (1986) Risk factors for bladder cancer in cohort exposed to aromatic amines. Cancer 58:2156

    Article  CAS  PubMed  Google Scholar 

  • Serth J, Kuczyk MA, Anton P, Hofner K, Jonas U (1995) Mutational inactivation of the P53 tumor suppressor gene as a prognosticator in muscle invasive bladder cancer. J Urol 153 (4): 534

    Google Scholar 

  • Shaaban AA, Tribukait B, El-Bedeiwy A-FA, Ghoneim MA (1990) Characterization of squamous cell bladder tumors by flow cytometric deoxyribonucleic and analysis: a report of 100 cases. J Urol 144:879

    CAS  PubMed  Google Scholar 

  • Shibata MA et al. (1989) The role of BBN in F344 rats. J Toxicol Environ Health 26 (3): 255–265

    Article  CAS  PubMed  Google Scholar 

  • Shimoyama A, Hiroshashi S (991) Expression of E- and P-cadherin in gastric carcinomas. Cancer Res 51: 2185–2192

    Article  CAS  PubMed  Google Scholar 

  • Skinner DG, Lieskovsky G (1984) Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 131:1069

    CAS  PubMed  Google Scholar 

  • Skinner DG, Crawford ED, Kaufman JJ (1980) Complications of radical cystectomy for carcinoma of the bladder. J Urol 123:640

    CAS  PubMed  Google Scholar 

  • Skinner DG, Tift JP, Kaufman JJ (1982) High dose, short course preoperative radiation therapy and immediate single stage radical cystectomy with pelvic node dissection in the management of bladder cancer. J Urol 127:671

    CAS  PubMed  Google Scholar 

  • Skinner DG, Daniels JR, Russell CA et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459

    CAS  PubMed  Google Scholar 

  • Skinner EC, Lieskovsky G, Skinner DG (1984) Radical cystectomy in the elderly patient. J Urol 131:1965

    Google Scholar 

  • Slack NH, Bross ID, Prout GR Jr (1977) Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 9:393

    Article  CAS  PubMed  Google Scholar 

  • Smaaland R, Akslen LA, Tonder B, Mehus A, Lote K, Albrektsen G (1991) Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol 67:61

    Article  CAS  PubMed  Google Scholar 

  • Smith JA Jr, Whitemore WF Jr (1981) Regional lymph node metastasis from bladder cancer. J Urol 126:591

    PubMed  Google Scholar 

  • Smith JA, Batata M, Grabstald H, Sogani PC, Herr W, Whitemore F (1982) Preoperative irradiation and cystectomy for bladder cancer. Cancer 49:869

    Article  PubMed  Google Scholar 

  • Smith NW, Strutton GM, Walsh MD, Wright GR, Seymour GJ, Lavin MF, Gardiner RA (1990) Transferrin receptor expression in primary superficial human bladder tumors indentifies patients who develop recurrences. Br J Urol 65:339–344

    Article  CAS  PubMed  Google Scholar 

  • Soloway MS (1984) Intravesical and systemic chemotherapy in the management of superficial bladder cancer. Urol Clin North Am 11:623

    CAS  PubMed  Google Scholar 

  • Soloway MS, Martino C (1976) Prophylaxis of bladder tumor implantation. Urology 7:29

    Article  CAS  PubMed  Google Scholar 

  • Sternberg CN, Yagoda A, Scher HI et al. (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cis-platin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461

    CAS  PubMed  Google Scholar 

  • Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R (1986) Radikale Zystektomie — Oft zu spät? Aktuel Urol 17:234

    Article  Google Scholar 

  • Stöckle M, Meyenburg W, Gertenbach U, Thüroff JW (1991a) Verbesserte überlebensraten nach radikaler Zystektomie durch M-VAC/M-VEC adjuvant. Urologe A [Suppl]:A73

    Article  CAS  PubMed  Google Scholar 

  • Stöckle M, Meyenburg W, Hohenfellner R (1991 b) M-VAC treatment of advanced or metastatic transitional cell carcinoma (TCC) of the urinary bladder. J Urol 145:494

    Google Scholar 

  • Stöckle M, Meyenburg W, Wellek S et al. (1995) Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153 (1): 47–52

    Article  PubMed  Google Scholar 

  • Stoter G (1985) Chemotherapy for metastatic bladder carcinoma. World J Urol 3:110

    Article  Google Scholar 

  • Studer UE, Hering F, Müller J, Schatzmann E (1991) Adjuvante Cisplatinum-Therapie nach Zystektomie bei Patienten mit Blasenkarzinom (SAKK 09/84). Urologe A [Suppl]:A72

    Article  CAS  PubMed  Google Scholar 

  • Tizzani A, Caseita G, Piana P, Piantino P (1989) CA-50 as tumour marker in transitional bladder carcinoma. Br J Urol 63:616

    Article  CAS  PubMed  Google Scholar 

  • Torti FM, Shortliffe LD, Williams RD et al. (1988) Alpha-interferon in superficial bladder cancer: a northern California oncology group study. J Clin Oncol 6:476

    CAS  PubMed  Google Scholar 

  • Tsujihashi H, Nakanishi A, Matsuda H, Uejima S, Kurita T (1991) Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 145:846–849

    CAS  PubMed  Google Scholar 

  • Uchibayashi T, Koshida K, Kunimi K, Hisazumi H (1995) Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder. Br J Cancer 71 (3): 625–628

    Article  CAS  PubMed  Google Scholar 

  • Uchida T, Wada C, Ishida H et al. (1995) p53 mutations and prognosis in bladder tumors. J Urol 153: 1097–1104

    Article  CAS  PubMed  Google Scholar 

  • UICC (1978) International Union Against Cancer: TNM classification of malignant tumors, Geneva (3rd rev. edn. 1987, 4th edn. 2nd rev. 1992). Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Varkarakis MJ (1974) Superficial bladder tumor, aspects of clinical progressions. Urology 4:414

    Article  CAS  PubMed  Google Scholar 

  • Vegt PDJ, Witjes A, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der Meijden APM (1995) A randomized study of intravesical mitomycin C, Bacillus Calmette-guerin tice and Bacillus Calmette-guerin rivm treatment in pTa-pTi Papillary carcinoma and carcinoma in situ of the bladder. J Urol 153:929–933

    Article  CAS  PubMed  Google Scholar 

  • Vleminckx K, Vakat L Jr, Mareel M, Fiers W, Van Roy F (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an in vasion suppressor role. Cell 66:107–119

    Article  CAS  PubMed  Google Scholar 

  • Vola MJ, Fromowitz F, Oravez S et al. (1986) Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314:133

    Article  Google Scholar 

  • Voges GE, Tauschke E, Stöckle M, Alken P, Hohenfellner R (1989) Computerized tomography: an anre-liable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol 142:972

    CAS  PubMed  Google Scholar 

  • Wallace DM, Bloom HJG (1976) The management of deeply infiltrating (T3) bladder carcinoma: controlled trial of radical radiotherapy versus pre-operative radiotherapy and radical cystectomy (first report). Br J Urol 54:136

    Google Scholar 

  • Werf-Messing B, Van der Hop WCJ (1981) Carcinoma of the urinary bladder (category T1, NX, Mo) treated either by radium implant or by transurethral resection only. Int J Radiat Oncol Biol Phys 7:299

    Article  PubMed  Google Scholar 

  • Wheeler JD, Hill WT (1954) Adenocarcinoma involving the urinary bladder. Cancer 7:119–124

    Article  CAS  PubMed  Google Scholar 

  • Whitmore WF Jr (1979) Therapeutic approaches based on disease assessment. Surgical management of low stage bladder cancer. Sem Concol 6/2:207

    Google Scholar 

  • Whitmore WF Jr, Batata M (1984) Status of integrated irradiation and cystectomy for bladder cancer. Urol Clin North Am 11:681

    PubMed  Google Scholar 

  • Whitmore WF, Batata MA, Ghoneim MA, Grabstald H, Unal A (1977 a) Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol 118:184

    PubMed  Google Scholar 

  • Whitmore WF, Batata MA, Hilaris BS et al. (1977 b) A comparative study of two preoperative radiation regimens with cystectomy for bladder cancer. Cancer 40:1977

    PubMed  Google Scholar 

  • WHO (1973) World Health Organization: International histological classification of tumors: Histological typing ofurinary bladder tumors. Geneva

    Google Scholar 

  • Williams RD, Sarosdy M, Catalona W (1988) Randomized trial of high vs low dose intra vesical interferon alpha 2b treatment of bladder carcinoma in situ. J Clin Oncol 7:121 (Abstract)

    Google Scholar 

  • Wishahi MM, Ismail IM, Rübben H, Otto T (1995) Keyhole-limpet hemocyanin immunotherapy in the bilharzial bladder: a new treatment modality? Phase II trial: superficial bladder cancer. J Urol 153:926–928

    Article  CAS  PubMed  Google Scholar 

  • Wolf H, Kakizoe T, Smith PH, Brosman SA, Okajima E, Rübben H, Utz DC (1986) Bladder tumors — treated natural history. In: Denis L, Niijima T, Prout G Jr, Schröder FH (eds) Development in bladder cancer. Liss, New York, pp 221–223

    Google Scholar 

  • Wynder EL, Goldsmith R (1977) The epidemiology of bladder cancer: a second look. Cancer 40:1246

    Article  CAS  PubMed  Google Scholar 

  • Yagoda A (1977) Future implications of phase 2 chemotherapy trials in 95 patients with measurable advanced bladder cancer. Cancer Res 37:2775

    CAS  PubMed  Google Scholar 

  • Yagoda A (1981) Chemotherapy of advanced bladder cancer. In: Conolly JG (ed) Carcinoma of the bladder. Raven, New York, pp 251

    Google Scholar 

  • Zabbo A, Montie JE (1984) Management of the urethra in men undergoing radical cystectomy for bladder cancer. J Urol 131:267

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Einrichtungen der Universität-GHS Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Herbert Rübben (Direktor der Urologischen Klinik und Poliklinik) (Direktor der Urologischen Klinik und Poliklinik)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rübben, H., Otto, T. (1997). Harnblasenkarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10731-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10731-7_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-10732-4

  • Online ISBN: 978-3-662-10731-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation